secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001193125-24-253174
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx Q3 net loss narrows; anito-cel hits 95% ORR in pivotal study with no neurotoxicity
--------------------------------------------------------------------------------

- Q3 net loss $25.9M ($39.3M YoY); collaboration revenue $26M from Kite expansion.
- Phase 2 iMMagine-1 (n=58): 95% ORR, 62% CR/sCR, median follow-up 10.3 months; 92% MRD negativity.
- Phase 1 anito-cel: 30.2-month mPFS, median OS not reached at 38.1 months; 100% ORR.
- No delayed neurotoxicity (parkinsonism, cranial nerve palsies) in >140 patients across trials.
- Cash $676.7M funds into 2027; first patients dosed in iMMagine-3 with Kite manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312524253174/0001193125-24-253174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312524253174/d862473d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-253174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer